Skip to main content
. 2011 Aug 11;61(1):41–48. doi: 10.1007/s00262-011-1089-0

Table 2.

AEs and irAEs occurring during treatment with ipilimumab

All grades, n Grade 3*, n
AEs/irAEs leading to discontinuation 0 0
AEs 10 0
irAEs
 Skin 5 0
 Gastrointestinal 4 1
 Liver 1 1
 Endocrine 1 0
 Hematologic 1 1
 Other 6 0
 Total 18 3

AEs adverse events, irAEs immune-related adverse events

* There were no grade 4 AEs or irAEs